Compare BRSP & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRSP | IRWD |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.2M | 850.8M |
| IPO Year | 2018 | 2010 |
| Metric | BRSP | IRWD |
|---|---|---|
| Price | $5.94 | $4.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $6.00 | $3.68 |
| AVG Volume (30 Days) | 618.2K | ★ 2.8M |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | ★ 10.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | $330,894,000.00 | ★ $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.02 | $37.22 |
| P/E Ratio | ★ N/A | $25.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $0.53 |
| 52 Week High | $6.32 | $5.78 |
| Indicator | BRSP | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 51.59 |
| Support Level | $5.88 | $4.42 |
| Resistance Level | $6.07 | $5.13 |
| Average True Range (ATR) | 0.14 | 0.35 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 21.74 | 27.91 |
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.